author-photo

Thomas A. Abrams

Harvard University

23

Papers

206

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.

2021 Digestive Diseases and Sciences
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 840: Gallstones and risk of cancers of the liver, biliary tract, and pancreas: A prospective study within two U.S. cohorts

2021 Epidemiology
Show All
- Source
- Cite
- Save
Citations (0)
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma

2021
Show All
- Source
- Cite
- Save
Citations (0)
FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (6)
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (9)
SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (28)